Anticoagulants Market Report 2026

The anticoagulants market size has grown rapidly in recent years. It will grow from $53.88 billion in 2025 to $60.42 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to high prevalence of cardiovascular diseases, increasing incidence of venous thromboembolism, long-standing use of warfarin, growth in hospital-based treatments, rising awareness of stroke prevention.

The anticoagulants market size is expected to see rapid growth in the next few years. It will grow to $97.07 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to growing atrial fibrillation population, expanding use of factor Xa inhibitors, improved safety profiles of NOACs, increasing outpatient anticoagulation management, rising adoption in emerging markets. Major trends in the forecast period include rising adoption of direct oral anticoagulants, shift from injectable to oral therapies, increasing long-term anticoagulation therapy use, growing focus on patient compliance and safety, expanding use in preventive cardiovascular care.

The rising prevalence of cardiovascular diseases is a major factor fueling the growth of the anticoagulants market in the coming years. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels. They represent the leading cause of death globally, with low- and middle-income countries accounting for approximately three-quarters of all CVD-related deaths. Anticoagulation pharmacotherapy, particularly direct oral anticoagulants, is widely used to reduce the risk of thrombosis across various cardiovascular conditions. For example, in September 2025, according to the British Heart Foundation, a UK-based charity, more than 7.6 million people in the UK - including over 4 million men and more than 3.6 million women - were living with cardiovascular disease, and projections suggest that, driven by an aging population and improved survival rates, this number could increase by around 1 million by 2030 and by about 2 million by 2040. Consequently, the growing incidence of cardiovascular diseases is driving the expansion of the anticoagulants market.

Leading companies operating in the anticoagulants market are concentrating on the development of advanced solutions such as factor Xa inhibitor tests to address the rising demand for testing driven by the increased use of direct oral anticoagulants for stroke prevention and other serious cardiovascular conditions. Factor Xa inhibitor tests are diagnostic assessments designed to measure the efficacy and safety of anticoagulant drugs that selectively inhibit factor Xa, thereby preventing blood clot formation in various clinical scenarios. For example, in February 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based biotechnology company, introduced coagulation tests for apixaban, edoxaban, and rivaroxaban. These newly launched factor Xa inhibitor coagulation tests use Roche’s innovative reagent cassette technology, delivering high-quality results and efficient sample processing while enabling standardization and automation to improve laboratory workflows. These tests play an important role in supporting clinical decision-making for patients using direct oral anticoagulants for stroke prevention, addressing the growing global need for reliable diagnostics in the management of serious conditions such as coronary artery disease and peripheral arterial disease.

In April 2025, Novartis, a Switzerland-based developer of innovative pharmaceuticals and biologics, acquired Anthos Therapeutics for up to $3.1 billion. Through this acquisition, Novartis intends to enhance its presence in the anticoagulant therapeutics market by progressing a late-stage Factor XI inhibitor with the potential to address major unmet needs in the treatment of thromboembolic diseases. Anthos Therapeutics is a US-based biopharmaceutical company focused on the development of monoclonal antibody-based anticoagulant therapies, including the Phase 3 investigational drug abelacimab for stroke prevention and cancer-associated thrombosis.

Major companies operating in the anticoagulants market are GlaxoSmithKline plc, Leo Pharma A/S, Amphastar Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Mylan N.V., Pfizer Inc., Sanofi S.A., Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca plc, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson, Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Natco Pharma Limited, Novartis International AG, Portola Pharmaceuticals Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Limited, and Zydus Cadila Healthcare Limited.

North America was the largest region in the anticoagulants market in 2025. The regions covered in the anticoagulants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anticoagulants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the anticoagulants market by increasing costs of imported active pharmaceutical ingredients, finished formulations, and specialized manufacturing inputs. This has affected pricing and availability of factor Xa inhibitors, heparins, and novel oral anticoagulants, particularly in regions reliant on pharmaceutical imports such as Asia-Pacific and Latin America. Hospital pharmacies and retail channels face margin pressure due to elevated procurement costs. However, tariffs are also encouraging local API production, regional manufacturing investments, and supply chain diversification, supporting long-term market resilience.

The anticoagulants market research report is one of a series of new reports that provides anticoagulants market statistics, including anticoagulants industry global market size, regional shares, competitors with a anticoagulants market share, detailed anticoagulants market segments, market trends and opportunities, and any further data you may need to thrive in the anticoagulants industry. This anticoagulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anticoagulants are drugs used to prevent and treat blood clots in the heart and blood vessels and are also commonly referred to as blood thinners. They work by slowing down the body’s clotting mechanism. Although called blood thinners, they do not actually thin the blood but instead prevent or reduce the formation of clots, also known as thrombi.

The primary drug classes of anticoagulants include Factor Xa inhibitors, heparin and LMWH, vitamin K antagonists, and others. Factor Xa inhibitors are anticoagulants that prevent clot formation by selectively and reversibly inhibiting the activity of clotting factor Xa. The various routes of administration include oral and injectable anticoagulants, which are distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Anticoagulants are used in the treatment of venous thromboembolism, atrial fibrillation or flutter, coronary artery disease, and other conditions, and are administered across settings including hospitals, home care, specialty centers, and others.

The anticoagulants market consists of sales of rivaroxaban, dabigatran, apixaban, and edoxaban. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.